You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 131 No. 1, January 1996 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Results of 280 liver resections for hepatocellular carcinoma

K. Takenaka, N. Kawahara, K. Yamamoto, K. Kajiyama, T. Maeda, H. Itasaka, K. Shirabe, T. Nishizaki, K. Yanaga and K. Sugimachi
Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

OBJECTIVE: To evaluate the recent results of liver resection in patients with hepatocellular carcinoma. DESIGN: Retrospective study. SETTING: A university hospital in Japan. PATIENTS: Two hundred eighty patients who underwent liver resection with complete extirpation of hepatocellular carcinoma from 1985 to 1993. MAIN OUTCOME MEASURES: Morbidity and survival after operation and the pathologic features of hepatocellular carcinoma according to the TNM classification of the International Union Against Cancer. RESULTS: More than 40% of the patients with stages I and II disease underwent a partial resection of the liver, whereas 50% of those with stages III and IVA were operated on with more than a bisegmentectomy. Fifty percent of all patients had no postoperative complications. The morbidities included intra-abdominal abscess (7%), bile leakage (5%), and hepatic failure (4%, of whom half died; mortality rate, 2%). Histopathologically, 32% of the stage I tumors were well differentiated (grade 1), while, in stage III, 56% had portal invasion and 61% had daughter lesions in the liver. The cumulative survival rates of patients with stages I, II, and III disease and all patients at 5 years were 69%, 52%, 32%, and 50%, respectively, while the disease-free survival rates at 5 years were 38%, 34%, 17%, and 29%, respectively. CONCLUSION: The recent results of liver resection for hepatocellular carcinoma are generally satisfactory; however, the recurrence rate is still high.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
Huynh et al.
Clin. Cancer Res. 2008;14:6146-6153.
ABSTRACT | FULL TEXT  

Adenovirus-delivered CIAPIN1 small interfering RNA inhibits HCC growth in vitro and in vivo
Li et al.
Carcinogenesis 2008;29:1587-1593.
ABSTRACT | FULL TEXT  

Use of Vascular Clamping in Hepatic Surgery: Lessons Learned From 1260 Liver Resections
Ercolani et al.
Arch Surg 2008;143:380-387.
ABSTRACT | FULL TEXT  

AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma
Huynh et al.
Molecular Cancer Therapeutics 2007;6:2468-2476.
ABSTRACT | FULL TEXT  

Percutaneous Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma After Hepatectomy: Long-term Results and Prognostic Factors
Choi et al.
Ann. Surg. Oncol. 2007;14:2319-2329.
ABSTRACT | FULL TEXT  

Role of Growth Factor Receptor Bound Protein 7 in Hepatocellular Carcinoma
Itoh et al.
Mol Cancer Res 2007;5:667-673.
ABSTRACT | FULL TEXT  

Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma
Huynh et al.
Molecular Cancer Therapeutics 2007;6:138-146.
ABSTRACT | FULL TEXT  

Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5
Liu et al.
Cancer Res. 2006;66:11851-11858.
ABSTRACT | FULL TEXT  

Overexpression of tumour suppressor retinoblastoma 2 protein (pRb2/p130) in hepatocellular carcinoma
Huynh
Carcinogenesis 2004;25:1485-1494.
ABSTRACT | FULL TEXT  

Elevated Expression of Valosin-Containing Protein (p97) in Hepatocellular Carcinoma Is Correlated With Increased Incidence of Tumor Recurrence
Yamamoto et al.
JCO 2003;21:447-452.
ABSTRACT | FULL TEXT  

A Possible Role for Insulin-like Growth Factor-binding Protein-3 Autocrine/Paracrine Loops in Controlling Hepatocellular Carcinoma Cell Proliferation
Huynh et al.
Cell Growth Differ. 2002;13:115-122.
ABSTRACT | FULL TEXT  

The Impact of New Technology on Hepatic Resection for Malignancy
Papadimitriou et al.
Arch Surg 2001;136:1307-1313.
ABSTRACT | FULL TEXT  

Clinicopathologic Features of Long-Term Survivors and Disease-Free Survivors After Resection of Hepatocellular Carcinoma: A Study of a Prospective Cohort
Poon et al.
JCO 2001;19:3037-3044.
ABSTRACT | FULL TEXT  

Hepatectomy for Hepatocellular Carcinoma: The Surgeon's Role in Long-term Survival
Fan et al.
Arch Surg 1999;134:1124-1130.
ABSTRACT | FULL TEXT  

Treatment Strategy for Patients With Cystic Lesions Mimicking a Liver Tumor: A Recent 10-Year Surgical Experience in Japan
Shimada et al.
Arch Surg 1998;133:643-646.
ABSTRACT | FULL TEXT  

A Thoracoabdominal Hepatectomy and a Transdiaphragmatic Hepatectomy for Patients With Cirrhosis and Hepatocellular Carcinoma
Takenaka et al.
Arch Surg 1998;133:80-83.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1996 American Medical Association. All Rights Reserved.